{"id":77078,"date":"2026-09-22T19:16:31","date_gmt":"2026-09-22T17:16:31","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/09\/22\/inducible-il-12-or-il-18-secreting-car-t-cells-targeting-the-glyco-antigen-cd176-exhibit-potent-activity-against-non-small-cell-lung-cancer-in-preclinical-models\/"},"modified":"2026-09-22T19:16:31","modified_gmt":"2026-09-22T17:16:31","slug":"inducible-il-12-or-il-18-secreting-car-t-cells-targeting-the-glyco-antigen-cd176-exhibit-potent-activity-against-non-small-cell-lung-cancer-in-preclinical-models","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/09\/22\/inducible-il-12-or-il-18-secreting-car-t-cells-targeting-the-glyco-antigen-cd176-exhibit-potent-activity-against-non-small-cell-lung-cancer-in-preclinical-models\/","title":{"rendered":"Inducible IL-12 or IL-18 secreting CAR T cells targeting the glyco-antigen CD176 exhibit potent activity against non-small cell lung cancer in preclinical models"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2026 Sep 22. doi: 10.1158\/2326-6066.CIR-25-1399. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>To date, non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths worldwide, underscoring the urgent need for new treatment options. The oncofetal carbohydrate CD176 is masked on healthy tissues but is present on a variety of cancer entities and is associated with cancer invasiveness and metastasis. In this study, we employed chimeric antigen receptor T cells (CAR-Ts) directed against CD176 for treatment of NSCLC. CD176-CAR-Ts were optimized with an additional inducible cassette encoding IL-18 (CD176-iIL18-TRUCKs) or IL-12 (CD176-iIL12-TRUCKs) to augment antitumor reactivity through autocrine and paracrine signaling. CD176-iIL18- and CD176-iIL12-TRUCKs eradicate NSCLC cells in a 3D tumor spheroid model and tissue slices derived from lung adenocarcinoma patients more potently than CD176-CAR-Ts. Administration of TRUCKs in a lung carcinoma xenograft mouse model results in partial or complete tumor eradication in all mice treated with CD176-iIL12-TRUCKs and in 50% of mice treated with CD176-iIL18-TRUCKs. This study highlights the potential of CD176 as a CAR-T-cell target and suggest CD176-CAR-Ts armored with IL-18 or IL-12 as promising new therapeutic approach for the treatment of NSCLC and several other CD176-positive cancer entities.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42770707\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20260922131631&amp;v=2.20.1\">42770707<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-1399\">10.1158\/2326-6066.CIR-25-1399<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2026 Sep 22. doi: 10.1158\/2326-6066.CIR-25-1399. Online ahead of print. ABSTRACT To date, non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths worldwide, underscoring the urgent need for new treatment options. The oncofetal carbohydrate CD176 is masked on healthy tissues but is present on a variety of cancer entities and &#8230; <a title=\"Inducible IL-12 or IL-18 secreting CAR T cells targeting the glyco-antigen CD176 exhibit potent activity against non-small cell lung cancer in preclinical models\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/09\/22\/inducible-il-12-or-il-18-secreting-car-t-cells-targeting-the-glyco-antigen-cd176-exhibit-potent-activity-against-non-small-cell-lung-cancer-in-preclinical-models\/\" aria-label=\"Read more about Inducible IL-12 or IL-18 secreting CAR T cells targeting the glyco-antigen CD176 exhibit potent activity against non-small cell lung cancer in preclinical models\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-77078","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/77078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=77078"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/77078\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=77078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=77078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=77078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}